Also see: Citi, Peabody: Analysts' New RatingsEditor's Note: Green and red arrows refer to intraday stock price movement. NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES Arch Capital ( ACGL) estimates were cut through 2011 at UBS. Reflects an increase of the second-quarter 2011 catastrophe loss estimate, UBS said. Maintain Neutral rating and $34 price target. Cliffs Natural Resources ( CLF) estimates were increased through 2013 at UBS. Company announces phase III development of Bloom Lake, UBS said. Maintain Neutral rating and $34 price dtarget. Campbell Soup ( CPB) estimates, target were raised at Goldman Sachs. Shares now seen reaching $34, and estimates were also increased, as a restructuring program was announced, Goldman said. Neutral rating. Goldman Sachs ( GS) numbers were lowered through 2013 at Credit Suisse. Company is facing difficult market conditions, Credit Suisse said. Outperform rating and new $170 price target. Harsco ( HSC) price target was cut at Jefferies to $38. Infrastructure business is still a work in progress, Jefferies said. Buy rating. Maidenform ( MFB) estimates, target were lowered at Citigroup. Shares now seen reaching $38. Estimates were also lowered, as sales have not been as robust as expected, Citigroup said. Buy rating. Morgan Stanley ( MS) numbers were reduced at Credit Suisse. Shares now seen reaching $33. Estimates also cut, given tougher market conditions, Credit Suisse said. Outperform rating. Nike ( NKE) estimates, target raised at Citigroup. Shares now seen reaching $98, according to Citigroup. Estimates also increased on renewed apparel growth and innovation in footwear. Buy rating. Progress Energy ( PGN) target cut at Jefferies. Shares of PGN now seen reaching $48.50, according to Jefferies. Company could face delays at Crystal River, Jefferies said. Hold rating. Rowan ( RDC) estimates were cut through 2012 at UBS. Reflects closing of LTI sale and fleet status update. Maintain Buy rating and $50 price target. Sigma Designs ( SIGM) estimates, target were reduced at UBS. Shares now seen reaching $8.50. Estimates also lowered on IPTV segment recovery and sales mix uncertainties, UBS said. Maintain Neutral rating. SYNNEX ( SNX) estimates, target cut at Goldman Sachs. Shares now seen reaching $33. Estimates also lowered citing Japan weakness, Goldman said. Neutral rating. Watson Pharmaceuticals ( WPI) estimates, target raised at Morgan Stanley. Shares now seen reaching $78, according to Morgan Stanley. Estimates also increased on lower-than-expected royalties on Concerta and Specifar accretion, Morgan Stanley added. Overweight rating. End of report.